K. Mody

A phase 1, open-label, multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in subjects with resected solid tumors and in combination with pembrolizumab in subjects with unresectable solid tumors (Keynote-603).

J. Frederick, D. Cho, T. Zaks, 2019, Journal of Global Oncology.

798 Safety, tolerability, and immunogenicity of mRNA-4157 in combination with pembrolizumab in subjects with unresectable solid tumors (KEYNOTE-603): an update

J. Bauman, H. Burris, J. Frederick, 2020 .

A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors.

Manish R. Patel, H. Burris, J. Frederick, 2019, Journal of Clinical Oncology.

767 Safety and preliminary efficacy of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L/IL-23/IL-36γ for intratumoral (ITu) injection, and durvalumab (IV) in TNBC, HNSCC, and melanoma

A. Jimeno, J. Frederick, S. Kummar, 2022, Regular and Young Investigator Award Abstracts.